1. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. (23rd January 2019) Authors: Robson, M E; Tung, N; Conte, P; Im, S -A; Senkus, E; Xu, B; Masuda, N; Delaloge, S; Li, W; Armstrong, A; Wu, W; Goessl, C; Runswick, S; Domchek, S M Journal: Annals of oncology Issue: Volume 30:Number 4(2019) Page Start: 558 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗